ResearchMoz

Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth

GBI Research
Published Date » 2013-10-09
No. Of Pages » N/A

GBI Research, a leading business intelligence provider, has released its latest research report “Asthma Market to 2019”. The asthma market is forecast to grow marginally over the forecast period across the leading eight developed nations, from $16.6 billion in 2012 to a projected value of $21.6 billion in 2019. This growth is expected despite the generic erosion facing the leading brands, and is a consequence of new market entrants and a disease prevalence that continues to rise, albeit not at rates as high as have been seen in the past. Some new, costly asthma therapies could be set to enter the asthma market, including GlaxoSmithKline’s (GSK’s) recently approved Relvar (fluticasone/vilanterol), and multiple monoclonal antibodies (mAbs). 

These include reslizumab, mepolizumab and lebrikizumab, which are being developed by Teva, GSK and Roche respectively. The mAbs, in particular, have the potential to change the asthma treatment landscape, most notably with regards to severe forms of the disease. Although such therapy may only play the role of an alternative treatment in the asthma treatment algorithm, their ability to reduce exacerbation rates has strong clinical and commercial value.

Scope

The report assesses the current asthma market, and forecasts market trends to 2019, analyzing key drivers and barriers. The areas covered include the following:

  • A disease introduction, which defines the disease, including symptoms, diagnosis and treatment
  • Analysis of the landscape of the asthma market, including a comparison of the efficacy and safety of the most prominent brands
  • Detailed analysis of the asthma pipeline, including, among other parameters, details of drug distribution by phase, molecule type and mechanism of action. The asthma clinical trial landscape is then analyzed, with a particular emphasis on failure rates across phases as well as trends in clinical trial size and duration, and by mechanism of action. This section also includes single-product forecasts for the most promising pipeline drugs.
  • An in-depth forecasting model for the asthma market, which considers the current marketed therapies, in addition to the potential market entry of new products. The model consists of a projected outcome, with high and low variance results, depending on the potential performance of pipeline therapies.
  • Analysis of strategic consolidations within the asthma indication, including co-development and licensing agreements
  • An overview of the drivers and barriers for the asthma market

Reasons to Buy

Primarily, the report will enable clients to establish a strong understanding of the asthma indication, helping to identify and understand market opportunities and the emerging competitive environment. It will also enable you to:

  • Understand the asthma pipeline and the factors that indicate that it is becoming more innovative. This is highlighted by the presence of numerous biologics in the pipeline, which look set to have a major impact upon the asthma market.
  • Observe detailed profiles for promising pipeline products, including revenue forecasts, and gain insights into how they are likely to compete in the market and who their main competitors will be.
  • Follow the trends in asthma clinical trial size and duration in relation to industry averages. In addition, the report will enable you to assess the potential risk of future developmental programs for asthma therapeutics, depending on the mechanism of action, by considering the recorded clinical trial failure rates.
  • Observe the potential growth patterns expected for the asthma market over the forecast period, and identify which countries are expected to contribute the most to this growth.
Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Introduction
2.2 Symptoms
2.3 Etiology
2.4 Pathophysiology
2.5 Diagnosis
2.6 Assessment of Disease Severity
2.7 Treatment
2.8 Treatment Algorithm

3 Marketed Products
3.1 Product Profiles
3.1.1 Advair Diskus (fluticasone and salmeterol) – GlaxoSmithKline
3.1.2 Symbicort (budesonide/formoterol) – AstraZeneca, Co-promotion with Astellas Pharma Inc
3.1.3 Singulair (montelukast) – Merck & Co
3.1.4 Xolair (omalizumab) – Novartis and Genentech
3.1.5 Foradil (formoterol) – Novartis (Co-marketed by Novartis and Schering Corporation)
3.1.6 Dulera/Zenhale (mometasone/formoterol) – Merck & Co
3.1.7 Relvar/Breo – GlaxoSmithKline/Theravance

4 Asthma Pipeline
4.1 Overview
4.2 Mechanisms of Action in the Pipeline
4.3 Clinical Trials
4.3.1 Failure Rate
4.3.2 Clinical Trial Duration
4.3.3 Clinical Trial Size
4.3.4 Comparative Clinical Trial Metrics Analysis
4.4 Promising Pipeline Molecules
4.4.1 Reslizumab – Teva Pharmaceutical ltd
4.4.2 Mepolizumab - GlaxoSmithKline
4.4.3 Lebrikizumab – Roche/Genentech
4.4.4 Veramyst - GlaxoSmithKline
4.4.5 Andolast – Rottapharm Madaus
4.4.6 Spiriva (Tiotropium Bromide) – Boehringer Ingelheim
4.5 Heat Map of Safety and Efficacy for Pipeline and Marketed Products

5 Market Forecast to 2019
5.1 Geographical Markets
5.1.1 Global Market
5.1.2 North America
5.1.3 Top Five Countries of Europe
5.1.4 Japan
5.2 Drivers and Barriers for the Asthma Therapeutics Market
5.2.1 Drivers
5.2.2 Barriers

6 Strategic Consolidations
6.1 Major Licensing Deals
6.2 Major Co-development Deals

7 Appendix
7.1 All Pipeline Drugs by Phase
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 Phase I
7.1.4 Phase II
7.1.5 Phase III
7.1.6 Filed
7.1.7 Undisclosed
7.2 Market Forecast to 2019
7.2.1 Global
7.2.2 US
7.2.3 Canada
7.2.4 UK
7.2.5 France
7.2.6 Germany
7.2.7 Italy
7.2.8 Spain
7.2.9 Japan
7.3 References
7.3.1 References for Pipeline Heat Map
7.3.2 References for Marketed Heat Map
7.4 Market Definitions
7.5 Abbreviations
7.6 Methodology
7.7 Coverage
7.8 Secondary Research
7.9 Therapeutic Landscape
7.10 Epidemiology-Based Forecasting
7.10.1 Analogous Forecasting Methodology
7.11 Market Size by Geography
7.11.1 Forecasting Model for Therapeutic Areas
7.12 Geographical Landscape
7.13 Pipeline Analysis
7.14 Competitive Landscape
7.14.1 Expert Panel Validation
7.15 Contact Us
7.16 Disclaimer

List of Tables


Table 1: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children of 0–4 Years of Age
Table 2: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children of 5–11 Years of Age
Table 3: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Youths = 12 Years of Age and Adults
Table 4: Management of Chronic Asthma
Table 5: Management of Acute Asthma
Table 6: Asthma Therapeutics Market, Global, Pipeline, Discovery, 2013
Table 7: Asthma Therapeutics Market, Global, Pipeline, Preclinical, 2013
Table 8: Asthma Therapeutics Market, Global, Pipeline, Phase I, 2013
Table 9: Asthma Therapeutics Market, Global, Pipeline, Phase II, 2013
Table 10: Asthma Therapeutics Market, Global, Pipeline, Phase III, 2013
Table 11: Asthma Therapeutics Market, Global, Pipeline, Filed, 2013
Table 12: Asthma Therapeutics Market, Global, Pipeline, Undisclosed, 2013
Table 13: Asthma, Global, Market Forecast, 2012–2019
Table 14: Asthma, US, Market Forecast, 2012–2019
Table 15: Asthma, Canada, Market Forecast, 2012–2019
Table 16: Asthma, UK, Market Forecast, 2012–2019
Table 17: Asthma, France, Market Forecast, 2012–2019
Table 18: Asthma, Germany, Market Forecast, 2012–2019
Table 19: Asthma, Italy, Market Forecast, 2012–2019
Table 20: Asthma, Spain, Market Forecast, 2012–2019
Table 21: Asthma, Japan, Market Forecast, 2012–2019

List of Figures


Figure 1: Asthma Therapeutics Market, Global, Pipeline, 2013
Figure 2: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, 2013
Figure 3: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, Phase I, 2013
Figure 4: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, Phase II, 2013
Figure 5: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, Phase III, 2013
Figure 6: Asthma Therapeutics Market, Global, Clinical Trial Failure Rate, 2013
Figure 7: Asthma Therapeutics Market, Global, Clinical Trial Failure Rates by Mechanism of Action, Phase I, 2013
Figure 8: Asthma Therapeutics Market, Global, Clinical Trial Failure Rates by Mechanism of Action, Phase II, 2013
Figure 9: Asthma Therapeutics Market, Global, Clinical Trial Failure Rates by Mechanism of Action, Phase III, 2013
Figure 10: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration, 2013
Figure 11: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Mechanism, Phase I, 2013
Figure 12: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Mechanism, Phase II, 2013
Figure 13: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Mechanism, Phase III, 2013
Figure 14: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size, 2013
Figure 15: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size by Mechanism, Phase I, 2013
Figure 16: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size by Mechanism, Phase II, 2013
Figure 17: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size by Mechanism, Phase III, 2013
Figure 18: Asthma Therapeutics Market, Global, Pipeline, Mechanism of Action Heat Map, 2012
Figure 19: Asthma Therapeutics Market, Global, Reslizumab Forecast ($m), 2014–2019
Figure 20: Asthma Therapeutics Market, Global, Mepolizumab Forecast ($m), 2015–2019
Figure 21: Asthma Therapeutics Market, Global, Lebrikizumab Forecast ($m), 2015–2019
Figure 22: Asthma Therapeutics Market, Global, Veramyst Forecast ($m), 2014–2019
Figure 23: Asthma Therapeutics Market, Global, Andolast Forecast ($m), 2015–2019
Figure 24: Asthma Therapeutics Market, Global, Tiotropium Bromide Forecast ($m), 2014–2019
Figure 25: Asthma Therapeutics Market, Global, Pipeline, Efficacy Heat Map, 2013
Figure 26: Asthma Therapeutics Market, Global, Pipeline, Safety Heat Map, 2013
Figure 27: Asthma Therapeutics Market, Global, Marketed Products, Safety and Efficacy Heat Map, 2013
Figure 28: Asthma Therapeutics Market, Global, Pipeline, Competitor Grid, 2013
Figure 29: Asthma Therapeutics Market, Global, Treatment Patterns, 2012–2019
Figure 30: Asthma Therapeutics Market, Global, Market Size, 2012–2019
Figure 31: Asthma Therapeutics Market, North America, Treatment Patterns, 2012–2019
Figure 32: Asthma Therapeutics Market, North America, Annual Cost of Treatment, 2012–2019
Figure 33: Asthma Therapeutics Market, North America, Market Size, 2012–2019
Figure 34: Asthma Therapeutics Market, Top Five EU Countries, Treatment Patterns, 2012–2019
Figure 35: Asthma Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment, 2012–2019
Figure 36: Asthma Therapeutics Market, Top Five EU Countries, Market Size ($bn), 2012–2019
Figure 37: Asthma Therapeutics Market, Japan, Treatment Patterns and Annual Cost of Treatment, 2012–2019
Figure 38: Asthma Therapeutics Market, Japan, Market Size, 2012–2019
Figure 39: Asthma Therapeutics Market, Global, Major Licensing Deals, 2006–2013
Figure 40: Asthma Therapeutics Market, Global, Major Licensing Deals, 2006–2013
Figure 41: Asthma Therapeutics Market, Global, Major Licensing Deals, 2006–2013
Figure 42: Asthma Therapeutics Market, Global, Major Licensing Deals, Completed and Terminated
Figure 43: Asthma Therapeutics Market, Global, Major Licensing Deals by Phase and Molecule Type, 2006–2012
Figure 44: Asthma Therapeutics Market, Global, Major Licensing Deals, Mechanism of Action
Figure 45: Asthma Therapeutics Market, Global, Major Co-developments by Region and Value, 2006–2013
Figure 46: Asthma Therapeutics Market, Global, Major Co-developments by Year, 2006–2013
Figure 47: Asthma Therapeutics Market, Global, Major Co-developments by Phase, 2006–2013
Figure 48: Asthma Therapeutics Market, Global, Major Co-developments by Phase and Molecule Type, 2006–2013
Figure 49: Forecasting Model for Therapeutic Areas

Upcoming Reports:

G-Protein Coupled Receptors (GPCRs) Market - Global Industry Size, Market Share, Trends, Analysis And Forecast, 2012 - 2018
By - Transparency Market Research
G protein coupled receptors which are also known by other names such as heptahelical receptors, G protein-linked receptors (GPLR), serpentine receptor and 7TM receptors comprises of a large family of protein. They are found in eukaryotes and choanoflagellates. GPCRs are targeted by approximately 45% to 50% of medicinal drugs. The major factors which are driving the growth of the GPCRs market include: growing researcher interest in targeting GPCR for medicinal drugs, development in indentifying new membrane structure and newer structures and the advancement in...
Animal Healthcare Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Animal healthcare products, which includes vaccines, antibiotics and medical feed, are used to provide a quality life to food producing and pet animals. Food producing animals include cattle, poultry, ship and fish, which provide protein via meat and dairy. Pet animals, such as dogs, cats and horses, are tamed animals kept for company or protection. In terms of end-users, the food producing animals dominates the animal healthcare market. Growing demand for safe meat and dairy products and growing concern of healthy pets are some of the major drivers of animal...
Self-Organizing Networks (SON) And Optimization Software Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
With growing number of mobile phone users every day and increasing network complexity, there is a rising demand for self organizing networks and optimization software to manage complex networks. As a result, future for SON and optimization software industry seems bright in the upcoming years. Implementation of 4G network resulted in network complexity, thus facilitating the need of effective technology to manage such complex networks. In anticipation of these issues, large operators have developed self organizing network technology to address these challenges.  Fourth...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Microsoft to Complete Nokia Purchase by April 25
Apr 23, 2014  
The Microsoft-Nokia deal that made headlines when it was announced is finally on its way to being completed. This proves that even the most complex deals do culminate with time. This week, Microsoft announced that it would complete the purchase of a major part of Nokia’s hardware assets by Friday. The much discussed deal-though on the brink of completion-has witnessed some adjustments...
Top End Stereo Systems Maker Harman Targets Chinese Auto Market
Apr 22, 2014  
Harman, the U.S.-based audio company that is best known as the provider of automobile stereos for top-end car models such as Mercedes-Benz, BMW and Ferrari, has said that it has signed agreements with two leading Chinese automakers—Chang’An and Geely. The company, that is associated with premium infotainment systems for leading auto makers, said that these new contracts...
Scientists Identify Cure for Dengue
Apr 18, 2014  
In a breakthrough discovery that can change the way dengue is treated, scientists have identified a drug target for the deadly dengue viruses. This discovery may help pave the way for discovery of vaccines that can cure this condition that affects nearly 390 million people throughout the world each year.  Scientists have used a new technique for this discovery to show that a region...
India is Facing a Cancer Crisis
Apr 15, 2014  
India is currently facing a cancer crisis – reports a recent research carried out at the King’s college London, in collaboration with the Tata Memorial Cancer Centre, Mumbai.  The reasons estimated for this crisis comprise of increasing rates of smoking, unequal access to proper treatment and belated diagnosis.  Every year, India witnesses around one...
Microparticle Tags to Check Counterfeit Goods Invented
Apr 14, 2014  
Researchers from the Massachusetts Institute of Technology have invented a new set of microparticles that can easily be read by smartphones and establish the authenticity of currency, electronic items and luxury goods.  This strategy is among those countless measures taken by big brands and companies to label their legitimate products in order to stop illegal copies of the...